Temporal Concept – Page 5

Sanofi Commits $20 Billion to US Expansion Amid Industry-Wide Investment Surge

2 months ago talkbio0Tagged drug production, Industry, Investments, pharmaceutical manufacturing, R&D, sanofi, supply chain, Surgical construction, trends qualifier, U.S.

Sanofi; US investment; pharmaceutical manufacturing; R&D; drug production; job creation; supply chain; industry trends

Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

2 months ago talkbio0Tagged AACR, Cancer of Neck, Clinical Trials, Event-Free Survival, Head, KEYNOTE-689 trial, Keytruda, locally advanced head, Merck, pembrolizumab, perioperative, recurrence prevention, Squamous cell carcinoma, United States Food and Drug Administration

Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

2 months ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Pivotal readouts on deck as Takeda sees stagnant sales this year

3 months ago talkbio0Tagged Growth, JPY, Phase 3, Pivotal, Sales - occupational activity, Takeda

Takeda, Phase 3, Pivotal, Growth, Sales – occupational activity, JPY

AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil

3 months ago talkbio0Tagged Ambulatory Care Facilities, Aortic Valve Insufficiency, Artificial Intelligence, Biotech Layoffs, biotechnology layoffs, Drug Discovery, Industry, Insitro, Market, Readiness, restructuring, trends qualifier

Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

3 months ago3 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

3 months ago talkbio0Tagged cholesterol, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, CTX310, Gene Modification, Genes, In Vivo, LDL Cholesterol Lipoproteins, Triglycerides

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes